<?xml version="1.0" encoding="UTF-8"?>
<p>Multiple societies have made recommendations for patient screening, including considerations for country‐specific policies, to identify populations to perform screening (Table 
 <xref rid="hep41480-tbl-0001" ref-type="table">1</xref>). Identification through screening remains challenging. Prior AASLD guidance had recommended screening all Americans born between 1945 and 1965.
 <xref rid="hep41480-bib-0020" ref-type="ref">20</xref> However, recent updates broaden the screening to include all U.S. adults aged 18 years or older,
 <xref rid="hep41480-bib-0021" ref-type="ref">21</xref> paralleling the recommendations made by the U.S. Preventive Services Taskforce to test those 18 to 79 years old.
 <xref rid="hep41480-bib-0014" ref-type="ref">14</xref> Identifying an optimally inclusive screening strategy will allow us to move toward treating the largest proportion of the chronic HCV‐infected population.
</p>
